Hepatocellular Carcinoma - Imaging and LI RADS Surveillance

Key Points

• LI-RADS diagnostic criteria apply only to defined high-risk populations.
• Ultrasound plus AFP every 6 months is a standard surveillance strategy for appropriate at-risk patients.
• Ultrasound visualization quality should be reported.
• Multiphasic CT or MRI is required to characterize a suspicious observation.
• LR-5 is diagnostic of HCC in the appropriate population without routine biopsy.
• LR-M means malignant but not specific for HCC and often warrants tissue diagnosis.
• AFP supports surveillance and risk assessment but is neither required nor sufficient for diagnosis.
• Management should occur in a multidisciplinary liver-tumor framework.

Algorithm

1. Determine whether the patient belongs to an HCC surveillance population.
2. Perform ultrasound plus AFP at approximately 6-month intervals when appropriate.
3. If surveillance detects a suspicious lesion or concerning AFP trend, obtain multiphasic CT or MRI.
4. Assign LI-RADS category from major and ancillary imaging features.
5. Treat LR-5 as HCC in the appropriate population and stage the disease.
6. Discuss LR-4, LR-M, tumor-in-vein, and complex cases in a multidisciplinary conference.
7. Select biopsy only when imaging is nondiagnostic and tissue will change management.
8. Continue surveillance after negative studies as long as the patient remains an appropriate treatment candidate.

Clinical Synopsis & Reasoning

Hepatocellular carcinoma can often be diagnosed noninvasively in the correct high-risk population because characteristic enhancement patterns are highly specific. LI-RADS was developed by the ACR to standardize surveillance, diagnostic CT/MRI interpretation, and communication. It is not intended for every focal liver lesion. Diagnostic LI-RADS categories apply primarily to adults at high risk, including many patients with cirrhosis and chronic hepatitis B, while certain conditions such as vascular causes of cirrhosis or pediatric disease require different approaches.

Surveillance aims to detect HCC before symptoms and while curative options remain available. AASLD recommends ultrasound with AFP about every 6 months for appropriate at-risk populations. Ultrasound quality must be reported because obesity, nodular cirrhosis, and steatosis can limit visualization. A suspicious lesion of sufficient size or a rising concerning AFP prompts multiphasic contrast-enhanced CT or MRI rather than repeated routine ultrasound.

On CT or MRI, the radiologist evaluates nonrim arterial-phase hyperenhancement, nonperipheral washout, enhancing capsule, observation size, and threshold growth along with ancillary features. Categories range from LR-1 definitely benign and LR-2 probably benign through LR-3 intermediate probability, LR-4 probably HCC, and LR-5 definite HCC. LR-M indicates malignancy that is not specifically HCC, such as cholangiocarcinoma or combined tumor. LR-TIV denotes tumor in vein. Treatment response has its own LI-RADS framework after locoregional therapy.

Treatment Strategy & Disposition

An LR-5 observation in an appropriate at-risk patient can usually be treated as HCC without biopsy. Biopsy is more often considered for indeterminate LR-4 lesions when the result will change management, LR-M lesions, or patients outside the population in which imaging criteria are diagnostic. AASLD emphasizes multidisciplinary review because transplant eligibility, resection, ablation, radiation, locoregional therapy, and systemic treatment depend on tumor stage, liver function, portal hypertension, and performance status.

Do not use AFP alone to diagnose or exclude HCC. Some cancers produce little AFP and benign liver inflammation can raise it. Likewise, a single arterial enhancing lesion is not automatically HCC; hemangioma, arterioportal shunt, focal nodular hyperplasia-like nodules, and non-HCC malignancy can mimic individual features. High-quality multiphasic timing is essential.

Surveillance should continue every 6 months in eligible patients even after a negative study. If ultrasound visualization is repeatedly inadequate, MRI- or CT-based strategies may be considered according to risk and local resources. Patients with Child-Pugh C cirrhosis who are not transplant candidates generally do not benefit from surveillance because they are unlikely to receive curative HCC therapy. The purpose of surveillance is actionable early detection, not simply finding more lesions.

Epidemiology / Risk Factors

• Most HCC arises in chronic liver disease, especially cirrhosis and chronic hepatitis B.
• Surveillance improves the chance of detecting tumors at a curable stage.
• Risk persists after hepatitis C cure when advanced fibrosis or cirrhosis remains.
• MASLD-associated HCC is increasing as metabolic liver disease becomes more prevalent.

Investigations

Reporting Essentials

Pharmacology

Prognosis / Complications

• Early-stage HCC may be cured by resection, transplantation, or ablation.
• Prognosis worsens with vascular invasion, extrahepatic spread, poor liver function, and poor performance status.
• Surveillance-detected tumors are more likely to be within curative-stage criteria.
• Underlying cirrhosis continues to influence mortality even when the tumor is successfully treated.

Patient Education / Counseling

• Explain that surveillance must occur every 6 months even when the previous ultrasound was normal.
• Tell patients when poor ultrasound visualization requires a different modality.
• Clarify that an LR-5 diagnosis can be sufficiently specific to avoid biopsy in the right population.
• Discuss transplant, resection, or locoregional options in terms of both tumor burden and liver function.
• Encourage ongoing treatment of viral hepatitis, alcohol use, obesity, diabetes, and smoking because liver and cardiovascular risk continue alongside cancer surveillance.

Notes

LI-RADS reduces ambiguity only when the examination is technically adequate and the population is appropriate. A category should not be assigned from a single-phase CT or to a patient with no HCC risk merely because the lesion looks similar.

Surveillance and diagnosis are different workflows. Ultrasound surveillance detects who needs diagnostic imaging; multiphasic CT or MRI then characterizes the observation. Repeated routine ultrasound is not an adequate response to a clearly suspicious lesion.

References

1. AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of HCC — Link
2. American College of Radiology: LI-RADS — Link